Masashi Hasebe

Masashi Hasebe

Auto-generated profile, based on publicly available information

Masashi Hasebe

Department of Human Genetics, McGill University, Montreal, Quebec, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
MHMasashi Hasebe
Masashi Hasebe
CSChen‐Yang Su
Chen‐Yang Su
YKYamato Keidai
Yamato Keidai
HMHiroto Minamino
Hiroto Minamino
Daisuke YabeDaisuke Yabe
Daisuke Yabe
SYSatoshi Yoshiji
Satoshi Yoshiji
Aims: To evaluate relationships of cardiovascular and kidney outcomes with glycemic or bodyweight reductions in randomised placebo‐controlled trials of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), incorporating data from FLOW and SOUL trials. Materials and Methods: PubMed and EMBASE were searched up to 22 August 2025 for placebo‐controlled randomized trials of oral or bolus‐type, subcutaneous GLP‐1RAs reporting major adverse cardiovascular events (MACE; a composite of cardiovascular death, myocardial infarction, and stroke) in adults with type 2 diabetes. The primary outcome was MACE; secondary outcomes included heart failure (HF) and kidney outcomes. Random‐effects meta‐analyses were followed by meta‐regression evaluating associations with HbA1c and bodyweight reduction. Results: A total of 73 263 individuals were included from 10 trials (ELIXA, LEADER, SUSTAIN‐6, EXSCEL, Harmony Outcomes, PIONEER 6, REWIND, AMPLITUDE‐O, FLOW, and SOUL). GLP‐1RAs reduced MACE by 14% (hazard ratio: 0.86; 95% CI: 0.82 to 0.91; p <0.001), as well as hospitalisation for HF and the composite kidney outcome (both p <0.001). Meta‐regression showed that every 1% extra reduction in HbA1c corresponded to a 27% lower HR for MACE ( p = 0.015; R 2 = 0.61). While HbA1c reduction was not significantly associated with secondary outcomes, the directionality was consistent with MACE. Bodyweight change was not associated with any of the analysed endpoints, including MACE ( p = 0.13; R 2 = 0.21). Conclusions: HbA1c reduction, not bodyweight change, was significantly and proportionally associated with MACE risk reduction. HbA1c lowering may serve as a useful surrogate for the cardiovascular improvements associated with GLP‐1RAs in type 2 diabetes.

21 January 2026 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
MHMasashi Hasebe
Masashi Hasebe
CSChen‐Yang Su
Chen‐Yang Su
HKHisashi Kamido
Hisashi Kamido
Daisuke YabeDaisuke Yabe
Daisuke Yabe
SYSatoshi Yoshiji
Satoshi Yoshiji
Aims: To evaluate the cardiovascular efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in Asian, Black or African American, and White populations, and to assess whether the magnitude of cardiovascular risk reduction differs across these populations. Materials and Methods: PubMed and EMBASE were searched to 11 November 2025 for randomized placebo‐controlled GLP‐1RA trials in adults with type 2 diabetes or overweight/obesity that reported race‐stratified major adverse cardiovascular events (MACE; cardiovascular death, non‐fatal myocardial infarction, or non‐fatal stroke). Hazard ratios (HRs) for MACE were extracted for Asian, Black or African American, and White populations. Random‐effects meta‐analyses were used to obtain pooled HRs and ratios of HRs (RHRs) comparing treatment effects between populations. Results: Nine trials, including the recent SOUL trial, were included, comprising 8164 Asian, 4036 Black or African American, and 62 503 White participants. GLP‐1RAs reduced MACE risk in Asian (HR 0.73; 95% CI 0.63–0.85; p < 0.001) and White populations (HR 0.86; 95% CI 0.81–0.91; p < 0.001). In Black or African American populations, the effect was similar to that in White populations (HR 0.88; 95% CI 0.67–1.15; p = 0.34) but did not reach statistical significance. The pooled RHR for Asian versus White populations was 0.84 (95% CI 0.71–0.98; p = 0.027), indicating a significantly greater risk reduction in Asian populations. The RHR for Asian versus Black or African American populations was 0.81 (95% CI 0.57–1.16; p = 0.25), with point estimates favouring Asian populations. Conclusions: GLP‐1RAs reduced MACE risk across populations, with greater relative risk reduction in Asian populations and broadly similar benefits in Black or African American and White populations.

25 August 2025 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
SYSatoshi Yoshiji
Satoshi Yoshiji
MHMasashi Hasebe
Masashi Hasebe
DTDaisuke Tanaka
Daisuke Tanaka
MSMasakazu Shimizu
Masakazu Shimizu
YSYuki Soma
Yuki Soma
NINobuya Inagaki
Nobuya Inagaki
Context: Monogenic diabetes is often underdiagnosed because of limited genetic testing opportunities and varying screening criteria. Objective: To investigate the genetic and clinical characteristics of monogenic diabetes in Japan and assess the utility of classical screening criteria and the maturity-onset diabetes of the young (MODY) probability calculator. Design and Setting: This study included a total of 232 probands with diabetes onset before age 35, BMI <30 kg/m², and negative islet autoantibodies, recruited from 2019 to 2024. Targeted sequencing of 11 causal genes was performed, followed by multiplex ligation-dependent probe amplification when indicated. Results: Pathogenic or likely pathogenic (P/LP) variants were identified in 67 (28.9%) probands: 25 in GCK, 22 in HNF1A, 7 in HNF1B, 6 in HNF4A, 4 in ABCC8, and 1 each in NEUROD1, PDX1, and INSR. Of these, 64 (95.5%) carried variants in actionable genes potentially affecting treatment strategies (GCK, HNF1A, HNF1B, HNF4A, ABCC8). P/LP carriers were younger at diagnosis, had lower BMI, and better metabolic control than noncarriers. However, clinical heterogeneity was substantial. Notably, 35 cases (52.2%) did not meet classical screening criteria of young-onset (≤25 years) and a three-generation family history. Although MODY probability scores were higher in probands with P/LP carriers (median: 75.5% vs. 58.0%; P <0.001), early insulin initiation substantially lowered the probability scores, warranting caution. Conclusion: We established a nationwide genetic testing platform and identified carriers of actionable variants, offering possibilities for precision medicine. Neither classical criteria nor the MODY calculator identified all monogenic cases, highlighting the need for broader genetic testing.

22 May 2023 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
YKYamato Keidai
Yamato Keidai
SYSatoshi Yoshiji
Satoshi Yoshiji
MHMasashi Hasebe
Masashi Hasebe
HMHiroto Minamino
Hiroto Minamino
TMTakaaki Murakami
Takaaki Murakami
NINobuya Inagaki
Nobuya Inagaki

1 August 2024 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
RTRyo Tsukaguchi
Ryo Tsukaguchi
MHMasashi Hasebe
Masashi Hasebe
KSKimitaka Shibue
Kimitaka Shibue
AHAkihiro Hamasaki
Akihiro Hamasaki
Diabetic striatopathy, a rare hyperglycemia complication, is characterized by chorea/ballism and striatal anomalies on neuroimaging, usually managed with glycemic control and haloperidol. However, practical strategies for haloperidol‐resistant cases are scarce. We describe a 76‐year‐old Japanese woman with diabetic striatopathy who initially presented with polydipsia, polyuria, and lower‐extremity weakness. Despite pronounced hyperglycemia (725 mg/dL), her blood glucose levels were reduced through saline infusion and intravenous insulin. Subsequently, she developed whole‐body ballism concomitant with striatal hyperintensity on T1‐weighted magnetic resonance imaging, which initially responded to haloperidol. Upon discontinuation of haloperidol, her symptoms relapsed and did not improve with the reintroduction of haloperidol. Dopamine transporter single photon emission computed tomography revealed diminished bilateral striatal uptake, suggesting presynaptic dopaminergic dysfunction. This finding prompted the initiation of L‐dopa, which significantly improved her symptoms. This case underlines the need to consider presynaptic dopaminergic dysfunction in diabetic striatopathy patients unresponsive to standard treatments, highlighting the effectiveness of L‐dopa in such scenarios.

11 October 2025 in Current Osteoporosis Reports
Verified
Journal Article
Closed access
PDF file
MHMasashi Hasebe
Masashi Hasebe
CSChen-Yang Su
Chen-Yang Su
DKDouglas P Kiel
Douglas P Kiel
SYSatoshi Yoshiji
Satoshi Yoshiji